Acute myeloid leukemia

Der Internist
Konstanze DöhnerHartmut Döhner

Abstract

In recent years, the development of novel molecular techniques has been instrumental in deciphering the genetic heterogeneity of acute myeloid leukemia (AML) as well as in gaining important insights into the pathomechanisms of AML. Genetic diagnostics has become an essential component in the initial work-up for disease classification, prognostication, and genotype-specific therapies. A major prerequisite for such individualized treatment strategies is a rapid pretherapeutic genetic analysis, which includes screening for the recurrent AML-associated gene fusions as well as mutations in the genes NPM1, FLT3, and CEBPA. Some of these molecular markers can be used for monitoring minimal residual disease and therefore provide clinically relevant information. There is an increasing number of promising molecularly targeted therapies in clinical development for distinct genetic AML subgroups. Solid data exist for the combination of all-trans retinoic acid and arsentrioxid in the treatment of acute promyelocytic leukemia; the addition of the immunoconjugate gemtuzumab ozogamicin (GO) to induction therapy has been shown to improve outcome in cytogenetic low- and intermediate-risk AML. Furthermore, there are encouraging data on the combin...Continue Reading

References

May 3, 2008·The New England Journal of Medicine·Richard F SchlenkUNKNOWN German-Austrian Acute Myeloid Leukemia Study Group
Jul 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrea CorbaciogluKonstanze Döhner
Dec 22, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan K BurnettKeith Wheatley
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido MarcucciHartmut Döhner
Jan 20, 2011·Current Opinion in Hematology·Amir Fathi, Mark Levis
May 11, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jan KrönkeKonstanze Döhner
Jul 12, 2011·Cancer Cell·Kathrin M BerntScott A Armstrong
May 3, 2013·The New England Journal of Medicine·UNKNOWN Cancer Genome Atlas Research NetworkGreg Eley
Jul 12, 2013·The New England Journal of Medicine·Francesco Lo-CocoUNKNOWN Study Alliance Leukemia
Aug 14, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan K BurnettDonald Milligan
Dec 10, 2013·Hematology·Peter Paschka, Konstanze Döhner
Nov 27, 2014·The New England Journal of Medicine·Siddhartha JaiswalBenjamin L Ebert

❮ Previous
Next ❯

Citations

Jul 16, 2016·American Journal of Hematology·Elihu Estey
Jan 8, 2021·Aging·Mario Morales-MartinezMario I Vega

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Related Papers

Gan to kagaku ryoho. Cancer & chemotherapy
Shigeki Ohtake
International Journal of Hematology
Andrea Kühnl, David Grimwade
© 2021 Meta ULC. All rights reserved